Daily Dilution Report - Apr 16, 2026
All Events
$SFST (MC: $469M)
- Direct Offering: 1.05M shares at $54.00/share. ($56.7M total).
- Over-allotment Option: Up to 157.5K additional shares at $54.00/share (expires by May 15, 2026).
- Stock Compensation Plans: 312,532 shares reserved.
$SFST (MC: $469M)
- Underwritten Public Offering of 1.05M shares at $54.00/share, raising ~$53.2M.
- Underwriters have option to purchase an additional 157,500 shares, bringing total proceeds to ~$61.3M if exercised.
$MGTX (MC: $916M)
- No direct stock dilution events affecting ordinary shares were identified in the filing.
$XWIN (MC: $310M)
- Private placement under Regulation S.
- 462,500 shares offered at $6.705/share, totaling ~$3.1M.
$CDNA (MC: $904M)
- The filing details a sale of a business segment for cash, which is a divestiture, not a dilution event for existing shareholders. The transaction involves CareDx, Inc. selling a portion of its business to Eurobio Scientific S.A. for $170 million in cash. This action would likely lead to a reduction in the company's assets and potentially its future revenue streams from that segment, but it does not involve the issuance of new equity that would dilute the ownership percentage of existing shareholders.
$MRLN (MC: $363M)
- Convertible Preferred Stock (21.71M shares issued): Potential conversion to up to 74.43M common shares (initial conversion price $12.00/share, subject to anti-dilution).
- Series A Warrants: Up to 21.16M shares issuable upon exercise at $12.00/share, includes full ratchet anti-dilution.
- Pre-PIPE Notes ($99M agg. principal) to convert into 10.24M Series A Preferred shares, plus 7.63M stock options ($3.30 W.A. EP).
$SFST (MC: $485M)
- Public Offering of Common Stock with Piper Sandler & Co. and Keefe, Bruyette & Woods, Inc. as underwriters.
- Over-allotment option: up to 15% additional common stock, exercisable within 30 days.
- Stock Compensation Plans: 312,532 shares reserved for issuance.
$YORW (MC: $446M)
- Direct Offering of common stock underwritten by Huntington Capital Markets.
- Underwriter's over-allotment option for additional shares.
- 589,429 shares reserved as of Dec 31, 2025 for future issuance/purchase via stock plans (Long Term Incentive, Employee Stock Purchase, Dividend Reinvestment).
$ALLO (MC: $529M)
- Direct Offering: 87.5M common shares at $2.00/share to raise $175M.
- ATM: 12.47M shares issued since 12/31/25 at weighted-average $1.68/share.
- Underwriters have 30-day option for an additional 13.1M shares at $2.00/share.
$WVE (MC: $1.4B)
- The filing describes a Redomiciliation where Wave Life Sciences Ltd. (a Singapore company) plans to become a Delaware corporation. This involves an exchange of existing ordinary shares for newly issued shares of common stock of the Delaware entity on a one-for-one basis. While this is a corporate restructuring that changes the legal domicile and potentially the structure of the parent entity, it is not a issuance of new capital that dilutes existing shareholders in the way that warrants, convertible notes, ATM programs, etc., do. The exchange is on a 1:1 basis, meaning existing shareholders will receive an equivalent number of shares in the new parent entity.
$USPH (MC: $1.2B)
- The filing primarily concerns the entry into a new credit agreement. While the credit agreement allows for potential future increases in debt and mentions the use of proceeds for acquisitions and growth opportunities (which could eventually lead to dilution if equity is used), this specific filing does not describe any instruments that directly dilute existing shareholders by issuing new shares or convertible securities at this time.